Pipeline new from Pfizer, Amgen, Genentech, and King-Devick

April 23, 2018

Company Drug/Device Medical Condition Status
Pfizer, Inc. PF-06939926 Duchenne muscular dystrophy (DMD) Phase Ib trial initiated
Synlogic SYNB1618 Phenylketonuria (PKU) Phase I/IIa trial initiated
NovoCure Ltd. STELLAR mesothelioma Phase II top-line results announced evaluating 80 subjects
Fervent Pharmaceuticals FP-101 vasomotor symptoms Phase IIa trials initiated enrolling 112 subjects from across the southeastern U.S.
Janssen Pharmaceutical Companies of Johnson & Johnson esketamine major depressive disorder at imminent risk for suicide Phase IIa results announced evaluating 68 subjects
Glenmark Pharmaceuticals GBR 830 moderate-to-severe atopic dermatitis Phase IIb trials initiated enrolling 392 subjects
Amgen Aimovig (erenumab) migraine Phase IIIb final results announced evaluating 246 subjects
Genentech, Inc. HEMLIBRA (emicizumab-kxwh) hemophilia A without factor VIII Breakthrough Therapy Designation granted by the FDA
King-Devick technologies, inc. K-D Balance conditions that could affect balance 510(k) clearance granted by the FDA
Alkermes ALKS 54641 major depressive disorder NDA filed with the FDA
NeuroVive Pharmaceutical AB KL1333 inherited mitochondrial respiratory chain diseases (MRCD) Orphan Drug Designation granted by the FDA
Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind (idarucizumab) patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding FDA approved